Two-year trends from the LANDMARC study: A 3-year, pan-India, prospective, longitudinal study on the management and real-world outcome in patients with type 2 diabetes mellitus

被引:0
|
作者
Das, Ashok K. [1 ]
Kalra, Sanjay [2 ]
Joshi, Shashank [3 ]
Mithal, Ambrish [4 ]
Kumar, K. M. Prasanna [5 ]
Unnikrishnan, Ambika G. [6 ]
Thacker, Hemant [7 ]
Sethi, Bipin [8 ]
Chowdhury, Subhankar [9 ]
Sugumaran, Amarnath [10 ]
Mohanasundaram, Senthilnathan [10 ]
Menon, Shalini K. [10 ]
Salvi, Vaibhav [10 ]
Chodankar, Deepa [10 ]
Thaker, Saket [10 ]
Trivedi, Chirag [10 ]
Wangnoo, Subhash K. [11 ]
Zargar, Abdul H. [12 ]
Rais, Nadeem [13 ]
机构
[1] Pondicherry Inst Med Sci, Pondicherry, India
[2] Bharti Hosp, Karnal, India
[3] Lilavati Hosp, Mumbai, India
[4] Medanta The Med, Gurgaon, India
[5] Ctr Diabet & Endocrine Care, Bengaluru, India
[6] Chellaram Diabet Inst, Pune, India
[7] Bhatia Hosp, Mumbai, India
[8] Care Hosp, Hyderabad, India
[9] IPGME & R & SSKM Hosp, Kolkata, India
[10] Sanofi, Sect 12,Kunjpura Rd, Mumbai 132001, Haryana, India
[11] Apollo Hosp Educ & Res Fdn, New Delhi, India
[12] Ctr Diabet & Endocrine Care, Srinagar, India
[13] Chowpatti Med Ctr, Mumbai, India
关键词
cardiovascular diseases; diabetes complications; diabetic nephropathies; glycaemic control; OBESITY;
D O I
10.1002/edm2.404
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: There are limited data on the real world management of diabetes in the Indian population. In this 2-year analysis of the LANDMARC study, the management of type 2 diabetes mellitus (T2DM) and related complications were assessed.Method: This multicenter, observational, prospective study included adults aged >= 25 to <= 60 years diagnosed with T2DM (duration >= 2 years at enrollment) and controlled/ uncontrolled on >= 2 anti-diabetic agents. This interim analysis at 2 years reports the status of glycaemic control, diabetic complications, cardiovascular (CV) risks and therapy, pan India including metropolitan and non-metropolitan cities.Results: Of the 6234 evaluable patients, 5318 patients completed 2 years in the study. Microvascular complications were observed in 17.6% of patients (1096/6234); macro vascular complications were observed in 3.1% of patients (195/6234). Higher number of microvascular complications were noted in patients from non-metropolitan than in metropolitan cities (p < .0001). In 2 years, an improvement of 0.6% from baseline (8.1%) in mean glycated haemoglobin (HbA1c) was noted; 20.8% of patients met optimum glycaemic control (HbA1c < 7%). Hypertension (2679/3438, 77.9%) and dyslipidaemia (1776/3438, 51.7%) were the predominant CV risk factors in 2 years. The number of patients taking oral anti-diabetic drugs in combination with insulin increased in 2 years (baseline: 1498/6234 [24.0%] vs. 2 years: 1917/5763 [33.3%]). While biguanides and sulfonylureas were the most commonly prescribed, there was an evident increase in the use of dipeptidyl peptidase-IV inhibitors (baseline: 3049/6234, 48.9% vs. 2 years: 3526/5763, 61.2%).Conclusion: This longitudinal study represents the control of T2DM, its management and development of complications in Indian population.
引用
收藏
页数:11
相关论文
共 33 条
  • [31] Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study
    Guisasola, F. Alvarez
    Mavros, P.
    Nocea, G.
    Alemao, E.
    Alexander, C. M.
    Yin, D.
    DIABETES OBESITY & METABOLISM, 2008, 10 : 8 - 15
  • [32] Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims
    Wang, Xuan
    Plantinga, Anna M.
    Xiong, Xin
    Cromer, Sara J.
    Bonzel, Clara-Lea
    Panickan, Vidul
    Duan, Rui
    Hou, Jue
    Cai, Tianxi
    JMIR DIABETES, 2024, 9
  • [33] Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D plus cohort study
    Sullivan, Sean D.
    Bailey, Timothy S.
    Roussel, Ronan
    Zhou, Fang Liz
    Bosnyak, Zsolt
    Preblick, Ronald
    Westerbacka, Jukka
    Gupta, Rishab A.
    Blonde, Lawrence
    DIABETES OBESITY & METABOLISM, 2018, 20 (09) : 2148 - 2158